Zacks: Regenxbio Inc. (RGNX) Given Average Rating of “Strong Buy” by Brokerages
Shares of Regenxbio Inc. (NASDAQ:RGNX) have been assigned a consensus broker rating score of 1.13 (Strong Buy) from the four brokers that provide coverage for the stock, Zacks Investment Research reports. One analyst has rated the stock with a buy rating and three have issued a strong buy rating on the company.
Brokerages have set a twelve-month consensus target price of $30.50 for the company and are anticipating that the company will post ($0.60) earnings per share for the current quarter, according to Zacks. Zacks has also assigned Regenxbio an industry rank of 105 out of 265 based on the ratings given to its competitors.
Several brokerages recently weighed in on RGNX. Piper Jaffray Cos. set a $25.00 target price on Regenxbio and gave the stock a “buy” rating in a research note on Thursday, August 18th. Zacks Investment Research downgraded Regenxbio from a “buy” rating to a “hold” rating in a research note on Thursday, July 7th. Finally, Chardan Capital restated a “buy” rating on shares of Regenxbio in a research note on Monday, August 22nd.
Hedge funds have recently bought and sold shares of the stock. Vivo Capital LLC purchased a new stake in Regenxbio during the first quarter valued at $10,697,000. BlackRock Advisors LLC increased its stake in Regenxbio by 27,318.5% in the second quarter. BlackRock Advisors LLC now owns 687,657 shares of the company’s stock valued at $5,501,000 after buying an additional 685,149 shares during the last quarter. Sabby Management LLC increased its stake in Regenxbio by 157.0% in the first quarter. Sabby Management LLC now owns 300,329 shares of the company’s stock valued at $3,244,000 after buying an additional 183,469 shares during the last quarter. Geode Capital Management LLC increased its stake in Regenxbio by 16.9% in the first quarter. Geode Capital Management LLC now owns 57,142 shares of the company’s stock valued at $617,000 after buying an additional 8,255 shares during the last quarter. Finally, State Street Corp increased its stake in shares of Regenxbio by 53.0% in the first quarter. State Street Corp now owns 88,025 shares of the company’s stock worth $950,000 after buying an additional 30,500 shares during the last quarter. Institutional investors and hedge funds own 68.73% of the company’s stock.
Regenxbio (NASDAQ:RGNX) opened at 16.15 on Friday. The company’s market cap is $427.41 million. The stock has a 50 day moving average price of $14.57 and a 200 day moving average price of $11.50. Regenxbio has a 1-year low of $7.07 and a 1-year high of $25.00.
Regenxbio (NASDAQ:RGNX) last announced its earnings results on Tuesday, August 9th. The company reported ($0.55) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.53) by $0.02. Regenxbio had a negative return on equity of 17.89% and a negative net margin of 451.73%. On average, equities research analysts anticipate that Regenxbio will post ($2.37) EPS for the current fiscal year.
REGENXBIO Inc is a biotechnology company. The Company is focused on the development, commercialization and licensing of recombinant adeno-associated virus (AAV) gene therapy. Its AAV gene delivery platform (its NAV Technology Platform) consists of rights to over 100 novel AAV vectors, including AAV7, AAV8, AAV9 and AAVrh10 (NAV Vectors).
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Regenxbio Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Regenxbio Inc. and related companies with MarketBeat.com's FREE daily email newsletter.